Claim Amendments

The following amendments use the claims as amended by the Examiner in the notice of allowability mailed on March 3, 2006.

1(currently amended). A compound of Formula (I) or (II)



(I)



(II)

wherein

A is nitrogen and B is carbon;

R^0 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl;

R^1 is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl;

X is $-C(R^{2a})(R^{2b})$, where R^{2a} and R^{2b} are each independently hydrogen, $(C_1\text{-}C_4)$alkyl, or halo-substituted $(C_1\text{-}C_4)$alkyl;

R^{3a} and R^{3b} are each independently hydrogen, $(C_1\text{-}C_4)$alkyl, or halo-substituted $(C_1\text{-}C_4)$alkyl; and

R^4 is a chemical moiety selected from the group consisting of $(C_1\text{-}C_8)$alkyl, aryl, heteroaryl, aryl$(C_1\text{-}C_4)$alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl$(C_1\text{-}C_3)$alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a ~~3 to 6~~ 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2(original). The compound of Claim 1 wherein R^4 is a chemical moiety selected from the group consisting of $(C_1\text{-}C_8)$alkyl, aryl$(C_1\text{-}C_4)$alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring(s), and ~~3 to 6~~ 3- to 8-

membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

3(original). The compound of Claim 2 wherein R^4 is $(C_1$-$C_8)$alkyl, halo-substituted $(C_1$-$C_8)$alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-1-yl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

4(original). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (I);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

5-12(cancelled).

13(previously presented). The compound of Claim 4 wherein R^{2a} and R^{2b} are hydrogen;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

14-16(cancelled).

17(previously presented). The compound of Claim 1 selected from the group consisting of

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-isopropyl-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2,2-trifluoro-ethyl)-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2-difluoro-ethyl)-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; and

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2-fluoro-ethyl)-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

or a solvate or hydrate of said compound.

18-32(cancelled).

33(original). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (II);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

34-44(cancelled).

45(currently amended). A compound of Formula (III) or (IV)



(III)



(IV)

wherein

A is nitrogen and B is carbon;

R^{0a}, R^{0b}, R^{1c}, and R^{1b} are each independently halo, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, or cyano;

n and m are each independently 0, 1 or 2;

X is $-C(R^{2a})(R^{2b})$, where R^{2a} and R^{2b} are each independently hydrogen, (C_1-C_4)alkyl, or halo-substituted (C_1-C_4)alkyl;

R^{3a} and R^{3b} are each independently hydrogen, (C_1-C_4)alkyl, or halo-substituted (C_1-C_4)alkyl; and

R^4 is a chemical moiety selected from the group consisting of (C_1-C_8)alkyl, aryl, heteroaryl, aryl(C_1-C_4)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C_1-C_3)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a ~~3-to-6-~~ 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents,

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

46(previously presented). The compound of Claim 45, 78, 79 or 80 wherein said compound is a compound of Formula (III);

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

47-50(cancelled).

51(previously presented). The compound of Claim 46 wherein R^{2a} and R^{2b} are hydrogen;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

52(previously presented) The compound of Claim 45, 78, 79 or 80 wherein said compound is a compound of Formula (IV);

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

53-56(cancelled).

57(previously presented). The compound of Claim 52 wherein R^{2a} and R^{2b} are hydrogen;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

58(previously presented). A pharmaceutical composition comprising (1) a compound of Claim 1, or a solvate or hydrate of said compound or said salt; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

59-76(cancelled).

77(previously presented). A compound having the following structure



78(currently amended). The compound of Claim 45 wherein R^4 is a chemical moiety selected from the group consisting of (C_1-C_8)alkyl, aryl(C_1-C_4)alkyl, ~~3 to 6~~ 3- to 8-membered partially or fully saturated carbocyclic ring(s), and 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

79(previously presented). The compound of Claim 78 wherein R^4 is (C_1-C_8)alkyl, halo-substituted (C_1-C_8)alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-1-yl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

80(previously presented). The compound of Claim 79 wherein R^4 is halo-substituted (C_1-C_8)alkyl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.